Get the Stockscreener App
0.7949
28.68%
0.1778
Plus Therapeutics Inc stock is traded at $0.7949, with a volume of 128.97M.
It is up +28.68% in the last 24 hours and up +74.14% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.6171
Open:
$0.8048
24h Volume:
128.97M
Relative Volume:
5.66
Market Cap:
$78.83M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.3142
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+87.60%
1M Performance:
+74.14%
6M Performance:
-31.54%
1Y Performance:
-57.08%
1-Day Range:
$0.7079
$0.8685
1-Week Range:
$0.3875
$0.8685
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.7941 | 61.26M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.78 | 98.90B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.53 | 58.51B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.97 | 59.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
717.75 | 43.55B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.92 | 35.81B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PSTV - Benzinga
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Why Cidara Therapeutics Was Such a Healthy Stock Today - AOL.com
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test - TipRanks
Plus Therapeutics (PSTV) Stock Rallies as UnitedHealthcare Approves Cancer Test Coverage - parameter.io
Why CytomX Therapeutics Stock Was Skyrocketing This Week - AOL.com
Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare - MSN
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients - ts2.tech
Massive Gains: 10 Stocks Investors Can’t Stop Buying - Insider Monkey
These 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLT - AOL.com
Plus Therapeutics Shares Surge After UnitedHealthcare Coverage Deal - MSN
Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments - TipRanks
Plus Therapeutics (PSTV) Rockets 40% on Major Insurance Win for Cancer Detection Tool – Here's Why Traders Are Buzzing - RagingBull
Plus Therapeutics Pops on UNH Pact - Baystreet.ca
Plus Therapeutics (PSTX) Surges After Securing UnitedHealthcare Coverage for CNSide Test - GuruFocus
Plus Therapeutics stock soars after UnitedHealthcare agreement By Investing.com - Investing.com South Africa
Plus Therapeutics stock soars after UnitedHealthcare agreement - Investing.com
PSTV: D. Boral Capital Maintains 'Buy' Rating with $5 PT | PSTV Stock News - GuruFocus
Plus Therapeutics rises on the back of UnitedHealthcare coverage deal - Seeking Alpha
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics announces national coverage agreement with UnitedHealthcare - TipRanks
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics Announces National Coverage Agreement - GlobeNewswire
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit - Yahoo Finance
51 Million Americans Gain Access: Plus Therapeutics' 92% Accurate Cancer Test Wins Major Insurance Deal - Stock Titan
Plus Therapeutics receives $1.9 million payment from cancer research fund By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT - GlobeNewswire
Plus Therapeutics receives $1.9 million payment from cancer research fund - Investing.com India
Plus Therapeutics receives $1.9M CPRIT payment for cancer program - MSN
Plus Therapeutics (PSTV) Analyst Rating Maintained at 'Buy' by D. Boral Capital | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Secures Additional $1.9M Funding from C - GuruFocus
Plus Therapeutics announces $1.9M advance payment from CPRIT - TipRanks
Plus Therapeutics, Inc. Secures $1.9 Million Payment from CPRIT as Part of $17.6 Million Grant for Leptomeningeal Cancer Treatment Development - Quiver Quantitative
$17.6M Cancer Research Grant: Plus Therapeutics Receives Second Payment for CNS Cancer Treatment Trial - Stock Titan
Fund Flows: Is Plus Therapeutics Inc. stock showing strong momentumEarnings Miss & Community Consensus Stock Picks - خودرو بانک
Market Pulse: Is Plus Therapeutics Inc forming bullish engulfing patterns2025 EndofYear Setup & Fast Gain Stock Trading Tips - خودرو بانک
Winners Losers: Should you avoid Plus Therapeutics Inc stock right nowWeekly Trade Analysis & Real-Time Buy Zone Alerts - khodrobank.com
Analyst Downgrade: What dividend growth rate does Plus Therapeutics Inc offerJuly 2025 Macro Moves & Entry Point Confirmation Alerts - خودرو بانک
Technical Analysis: What dividend growth rate does Plus Therapeutics Inc offer2025 Support & Resistance & Stepwise Swing Trade Plans - خودرو بانک
Should you avoid Plus Therapeutics Inc. stock right nowJuly 2025 Big Picture & High Conviction Investment Ideas - khodrobank.com
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide Diagnostics Clinical Laboratory - citybiz
Plus Therapeutics Announces Successful Accreditation and - GlobeNewswire
Breakout Watch: Can Plus Therapeutics Inc reach all time highs this yearMarket Risk Report & Community Verified Trade Alerts - خودرو بانک
Plus Therapeutics (PSTV) Rating Maintained as 'Buy' by D. Boral Capital | PSTV Stock News - GuruFocus
CNSide Diagnostics Achieves Key Accreditation Milestone for Hous - GuruFocus
Aug Wrap: What is the dividend yield of Plus Therapeutics IncMarket Trend Summary & Community Trade Idea Sharing Platform - khodrobank.com
Major Regulatory Milestone: Plus Therapeutics' CNSide Lab Gets Federal Approval for CNS Cancer Testing - Stock Titan
Aug Momentum: Will Plus Therapeutics Inc. benefit from sector rotation2025 Market Trends & Technical Pattern Based Signals - خودرو بانک
Returns Recap: What is Plus Therapeutics Inc.’s valuation compared to sectorQuarterly Performance Summary & Consistent Profit Trade Alerts - khodrobank.com
Levels Update: What is the long term forecast for Plus Therapeutics Inc. stockIPO Watch & Comprehensive Market Scan Insights - khodrobank.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):